Scarica l'app Stockscreener
11.71
1.56%
0.18
Precedente Chiudi:
$11.53
Aprire:
$11.54
Volume 24 ore:
332.99K
Relative Volume:
0.53
Capitalizzazione di mercato:
$815.95M
Reddito:
$62.71M
Utile/perdita netta:
$-112.51M
Rapporto P/E:
-7.755
EPS:
-1.51
Flusso di cassa netto:
$-96.01M
1 W Prestazione:
+3.58%
1M Prestazione:
+4.09%
6M Prestazione:
-23.91%
1 anno Prestazione:
+24.84%
Intervallo 1D:
$11.51
$11.79
Intervallo di 1 settimana:
$10.93
$12.20
Portata 52W:
$8.21
$17.70
Zymeworks Inc. Stock (ZYME) Company Profile
Nome
Zymeworks Inc.
Settore
Industria
Telefono
604-678-1388
Indirizzo
1385 West 8th Avenue, Suite 540, Vancouver, BC
Confronta ZYME con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ZYME
Zymeworks Inc.
|
11.71 | 787.77M | 62.71M | -112.51M | -96.01M | -1.51 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-16 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-11-07 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-11-01 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-03-21 | Ripresa | Wells Fargo | Overweight |
| 2023-01-04 | Reiterato | H.C. Wainwright | Neutral |
| 2022-12-20 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-11-01 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2022-10-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-10-04 | Ripresa | Wells Fargo | Overweight |
| 2022-05-05 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-03-15 | Iniziato | Evercore ISI | Outperform |
| 2021-12-10 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-17 | Ripresa | Guggenheim | Neutral |
| 2021-10-07 | Iniziato | Jefferies | Hold |
| 2021-03-31 | Iniziato | Credit Suisse | Outperform |
| 2021-02-25 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-02-08 | Ripresa | H.C. Wainwright | Buy |
| 2021-01-25 | Downgrade | Citigroup | Buy → Neutral |
| 2020-09-29 | Ripresa | JP Morgan | Neutral |
| 2020-08-06 | Iniziato | SVB Leerink | Outperform |
| 2020-01-10 | Iniziato | Wolfe Research | Outperform |
| 2019-12-09 | Iniziato | JP Morgan | Neutral |
| 2019-11-25 | Iniziato | H.C. Wainwright | Buy |
| 2019-11-20 | Iniziato | Guggenheim | Buy |
| 2019-09-30 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2019-08-30 | Iniziato | Stifel | Buy |
| 2019-07-18 | Iniziato | Deutsche Bank | Buy |
| 2018-05-11 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2018-03-19 | Iniziato | Raymond James | Outperform |
Mostra tutto
Zymeworks Inc. Borsa (ZYME) Ultime notizie
Price T Rowe Associates Inc. MD Raises Stock Position in Zymeworks Inc. (NYSE:ZYME) - Defense World
Wall Street Analysts Think Zymeworks (ZYME) Could Surge 83.89%: Read This Before Placing a Bet - NewsBreak: Local News & Alerts
Analyst Forecasts For Zymeworks Inc. (NASDAQ:ZYME) Are Surging Higher - Yahoo Finance
Analysts Just Shipped A Stunning Upgrade To Their Zymeworks Inc. (NASDAQ:ZYME) Estimates - simplywall.st
Zymeworks Reports Q1 2025 Financial Results and R&D Progress - TipRanks
Zymeworks Inc. (NYSE:ZYME) Q1 2025 Earnings Call Transcript - Insider Monkey
Zymeworks Inc. (ZYME) Reports Q1 Loss, Tops Revenue Estimates - MSN
Zymeworks Inc (ZYME) Q1 2025 Earnings Call Highlights: Revenue S - GuruFocus
Dimensional Fund Advisors LP Purchases 123,240 Shares of Zymeworks Inc. (NYSE:ZYME) - Defense World
Zymeworks Inc (ZYME) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic Partnerships ... - Yahoo Finance
Zymeworks Inc (ZYME) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic Partnerships ... By GuruFocus - Investing.com Canada
Zymeworks Inc (ZYME) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic Partnerships Propel Growth - GuruFocus
Zymeworks (ZYME) Surpasses Revenue Expectations in Q1 | ZYME Sto - GuruFocus
Zymeworks Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Zymeworks May 2025 slides: Pipeline expansion amid modest revenue growth - Investing.com Australia
Zymeworks Inc (ZYME) Q1 2025 Earnings: EPS of -$0.30 Beats Estimate, Revenue Surges to $27.1 Million - GuruFocus
Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results - GlobeNewswire
Zymeworks Inc (ZYME) Q1 2025 Earnings Report Preview: What To Ex - GuruFocus
Zymeworks Inc. (NYSE:ZYME) Shares Sold by Envestnet Asset Management Inc. - Defense World
Invesco Ltd. Reduces Position in Zymeworks Inc. (NYSE:ZYME) - Defense World
Zymeworks Inc. (NYSE:ZYME) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Q2 Earnings Forecast for Zymeworks Issued By Leerink Partnrs - Defense World
A new trading data show Zymeworks BC Inc (ZYME) is showing positive returns. - Sete News
Zymeworks (ZYME) Expected to Announce Earnings on Thursday - Defense World
Zymeworks: A Strong Buy With Newly-Approved Cancer Drug, Excellent Financials, And Expansive Pipeline - Seeking Alpha
Zymeworks: Poised For Growth With Platform Validation - Seeking Alpha
Press Release Distribution & PR Platform - ACCESS Newswire
JPMorgan Chase & Co. Grows Stake in Zymeworks Inc. (NYSE:ZYME) - Defense World
Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting - Koreabizwire
Zymeworks Presents New Data from Multiple Development Programs a - GuruFocus
Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting | ZYME Stock News - GuruFocus
Zymeworks Inc. Presents Promising Preclinical Data on Antibody-Drug Conjugates and T Cell Engagers at AACR Annual Meeting 2025 - Nasdaq
Zymeworks Unveils Breakthrough Cancer Drug Data: T-Cell Engagers Show Strong Activity in Lung, Ovarian Cancers - Stock Titan
Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development - The Financial World
Zymeworks appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development - MediaNews4U
Zymeworks Strengthens Clinical Leadership with New Senior VP Appointment - TipRanks
Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Cl - GuruFocus
Zymeworks Strengthens Cancer Drug Pipeline: Top Oncology Expert Takes Helm of Clinical Development - Stock Titan
Major Investment Alert: Ecor1 Capital Boosts Stake in Zymeworks! - TipRanks
Zymeworks to Announce Q1 2025 Financial Results and Host Conference Call - TipRanks
Zymeworks to Report First Quarter 2025 Financial Results and Ho - GuruFocus
Zymeworks Inc. to Announce First Quarter 2025 Financial Results on May 8, 2025 - Nasdaq
Zymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025 - GlobeNewswire
Clinical-Stage Biotech Zymeworks Sets Q1 2025 Earnings Date: Key Updates Expected - Stock Titan
Zymeworks Inc. (ZYME): Among Stocks Insiders Bought in April After Trump’s Tariff Rollout - Yahoo Finance
20 Stocks Insiders Bought in April After Trump’s Tariff Rollout - Insider Monkey
Zymeworks sees $3.62 million stock purchase by EcoR1 Capital - Investing.com Nigeria
Zymeworks Inc. Azioni (ZYME) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.54%
7.58%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):